Ligand validation:2GL9

ASN: ASPARAGINE

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
2GL9_ASN_D_597	58%	45%	0.112	0.891	1.01	1.02	-	-	2	0	100%	0.38
2GL9_ASN_B_297	57%	66%	0.104	0.879	0.73	0.45	-	-	0	0	100%	0.8
2CG4_ASN_B_1153	100%	52%	0.025	0.995	0.94	0.79	1	-	1	0	100%	1
3H0L_ASN_J_904	100%	24%	0.031	0.993	1.24	1.76	1	1	0	0	100%	1
8H46_ASN_B_407	100%	45%	0.033	0.992	0.83	1.18	-	1	1	0	100%	1
3KXA_ASN_B_140	100%	38%	0.032	0.988	1.05	1.25	1	1	0	0	100%	1
8H48_ASN_B_409	100%	56%	0.035	0.991	0.79	0.78	-	-	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729. RCSB PDB uses resources of the National Energy Research Scientific Computing Center (NERSC), a Department of Energy User Facility.